<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715960</url>
  </required_header>
  <id_info>
    <org_study_id>2016 AW/CSU/PS</org_study_id>
    <nct_id>NCT02715960</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules</brief_title>
  <official_title>Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In an early clinical research, 138 patients completed the treatment of Psoriasis Vulgaris by
      Acitretin Capsules in 8 weeks, the results indicate 75 cases effectively (54.3%), 50 cases
      invalid(36.2%), 13 cases serious(9.4%). To investigate the influence of genetic factors on
      the curative effect and find the relationships between genetic variants and the response of
      Acitretin Capsules to treatment of Psoriasis Vulgaris.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators analyzed the various levels of genetic factors, including: 1.To analysis the
      key gene variants which associated with ADME affect the efficacy of Acitretin Capsules;
      2.Direct full genetic sequencing of MHC genes, to explore the genetic variations of efficacy
      and side effects; 3. Direct sequencing of all exons in the gene in the patients of the
      response of serious and effectively, to explores the rare genetic variation may cause
      deterioration of treatment by Acitretin Capsules.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease control rate</measure>
    <time_frame>8 weeks after the first treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>single-arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acitretin Capsules</intervention_name>
    <description>During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.</description>
    <arm_group_label>single-arm</arm_group_label>
    <other_name>Tretinoin, Vitamine A Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed according to Classification criteria for Psoriasis vulgaris

          2. Patients aged 18 to 70 years (to the date of screening)

          3. PASI grade â‰¥7point

          4. Not treatment in the Topical corticosteroids, Immunosuppression, Biologicals agents or
             Tretinoin cream, Phototherapy nearly one months before enrolled.

          5. Total bilirubin &lt; 1.5 x ULN, AST(SGOT)/ALT(SGPT) &lt;2.5 x ULN if not liver metastases&lt;5
             x ULN if known liver metastases, Creatinine clearance &lt;1.5 x ULN

          6. Understanding the whole process of the study, voluntary participation and signed the
             informed consent

        Exclusion Criteria:

          1. Pregnant women, ready to pregnant or lactating women

          2. Have a serious heart, lung, kidney and other vital organs and endocrine system lesions
             and the history

          3. Patients is liver function abnormal persons (ALT above the center laboratory normal
             limit) or hepatitis b patient grain carriers

          4. Patients with chronic diarrhea, or peptic ulcer nearly 1 year

          5. Patients suffering from malignant tumor

          6. Patients suffering from acute and chronic infectious diseases

          7. Mental disorders, history of alcohol abuse, drug or other substance abuse

          8. Other cases which researchers believe that can not enroll
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiang Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yijing He, PhD,MD</last_name>
    <phone>+86-1587481262</phone>
    <email>yijinghe@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yijing He, MD, PhD</last_name>
      <phone>+86-1587481262</phone>
      <email>yijinghe@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Yijing He</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>data not entered</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

